ML-162
CAY-20455-1 1 mg
Data Sheet: 
SDS:
SDS:
CAS
1035072-16-2
Formulation
A crystalline solid
Purity
≥95%
MW
477,4
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A GPX4 and TrxR1 inhibitor; covalently binds to the GPX4 active site residue Sec46 and allosteric site residue Cys66 but does not inhibit recombinant human GPX4 activity in a cell-free assay; inhibits TrxR1 in a cell-free assay (IC50 = 19.5 µM); inhibits TrxR1 in A549 cells at 0.5-15 µM; decreases GPX4 levels in MDA-MB-231 breast cancer cells; reduces the viability of BT-549 breast cancer cells, an effect that can be enhanced by α-eleostearic acid; induces Ras-synthetic lethality in mutant RAS oncogene-expressing cells (IC50s = 25 and 578 nM for HRASG12V-expressing and wild-type RAS-expressing BJeH cells, respectively)
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
